← The Wire·Earnings·

CVS warns medical-cost growth remains at high trend; UnitedHealth, Oscar shares fall

CVS said medical-cost growth remains at a high trend, sending Oscar and UnitedHealth shares lower. The read-through keeps utilization and margin pressure at the center of the managed-care setup, with no company-specific offset established in the report.

STOCK PHOTO · STEPHEN LEONARDI

The story

CVS expects medical-cost growth to remain at a "high trend," signaling that elevated utilization or treatment costs continue to pressure the managed-care sector. Oscar and UnitedHealth shares declined following the update.

The comment extends the sector's existing concern over medical-cost inflation rather than introducing a clearly defined new financial target. CVS's FY 2025 revenue was $402.1B, up 7.8% year over year, while UnitedHealth reported $447.6B of revenue, up 11.8%; those annual figures provide scale but do not establish how current cost growth is affecting margins.

For CVS, the mechanism is direct: higher medical costs can compress the profitability of its insurance operations. UnitedHealth is exposed through its health-benefits business, while Oscar's insurance-focused model makes the same utilization trend relevant to claims costs and underwriting performance.

The size and duration of the earnings effect remain unresolved. The next useful evidence would be the companies' next earnings disclosures and any updated medical-cost or loss-ratio commentary. Those updates would show whether the warning is contained to CVS or represents a broader deterioration across managed care.

Our read · Wed, Sep 9

The high-trend cost warning shifts the sector read to the downside for CVS, UNH and OSCR as medical-cost pressure threatens managed-care margins.

Why. The immediate implication is margin risk across managed care: sustained high medical-cost growth can raise claims expense faster than insurers can reprice coverage. CVS's 0.4% FY 2025 net margin leaves limited disclosed profitability cushion.

Both cases

The case it holdsCVS generated $402.1B of FY 2025 revenue and could absorb the cost signal if pricing, benefit design, or other operating actions offset higher claims.
The case it breaksThe reported high-trend cost growth is a direct claims-cost headwind, and CVS’s 0.4% FY 2025 net margin underscores the sensitivity of earnings to further pressure.

What could change this view: The trade read fails if subsequent company commentary shows the high-trend cost pressure is already priced into guidance or offset by pricing and operating improvements.

CVS Health stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Yahoo FinanceoriginalWed, Sep 9 · 2:05 PM ETCVS Still Sees 'High-Trend' Cost Growth; Oscar, UNH Stock Fall

Since this story · the companies named here, equal weight · −16.0%

Sep 9 · first close after publicationNov 19

Price context does not establish that the story caused the move.

Keep reading

More on CVS

CVS Health plans split between pharmacy and insurance businessesCVS raises 2026 EPS guidance floor to $6.98 after revenue reaches $108.4BHealth insurers withdrawing Medicare Advantage plans, affecting seniors in rural markets

Latest on the Wire

Beijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesChina seeks protections to restart US private-equity investmentsAMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions rise
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Yahoo Finance as CVS Still Sees 'High-Trend' Cost Growth; Oscar, UNH Stock Fall, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →